NCT03661125 - SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 11, 2019

Primary Completion Date

September 1, 2021

Study Completion Date

September 1, 2021

Conditions

Parkinson Disease Psychosis

Interventions

DRUG

Saracatinib

AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/49. Two tablets to be taken every morning for 14 days.

DRUG

Placebo Oral Tablet

Placebo AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/37. Two tablets to be taken every morning for 14 days.

Trial Locations (1)

RECRUITING

Mitul Mehta, London